Abstracts Archive - Page 547 of 1683 - ATC Abstracts

2020 American Transplant Congress
Factors Associated with Hepatocellular Carcinoma Understaging for Liver Transplantation, and Variation in Understaging by Transplant Center
N. Mahmud¹, M. Hoteit¹, D. Goldberg²
¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²University of Miami, Miami, FL
*Purpose: Hepatocellular carcinoma (HCC) may be cured by liver transplantation (LT) in selected patients, though recurrence rates remain high. Patients who are reported as within…
2020 American Transplant Congress
National Trends in Locoregional Therapy among Liver Transplant (LT) Candidates with Hepatocellular Carcinoma (HCC) in the United States
A. Kwong¹, W. Kim¹, F. Yao², N. Mehta²
¹Stanford University, Redwood City, CA, ²University of California, San Francisco, San Francisco, CA
*Purpose: Advances in locoregional therapy (LRT) have expanded treatment options for patients with HCC. As recent policy changes in the United States (US) have lengthened…
2020 American Transplant Congress
Potential Benefits of Y-90 Radiation Microspheres for Bridging Liver Candidates with Hepatocellular Carcinoma to Liver Transplant
S. Pelletier¹, J. Durden², S. Shan², P. Vargas³, N. Goldaracena¹
¹University of Virginia Health System, Charlottesville, VA, ²School of Medicine, University of Virginia Health System, Charlottesville, VA, ³Department of Surgery, University of Virginia Health System, Charlottesville, VA
*Purpose: In October 2015, the UNOS policy for hepatocellular carcinoma (HCC) exception scores was changed to modify the maximum exception value and prolong the time…
2020 American Transplant Congress
Younger Age is Associated with Improved Survival in Patients Undergoing Liver Transplantation Alone for Metastatic Neuroendocrine Tumors
R. Gedaly, D. Valvi, X. Mei, M. Gupta, M. Shah, A. Ancheta, F. Marti
University of Kentucky, Lexington, KY
*Purpose: Neuroendocrine tumor (NET) metastases are a major cause of morbidity and mortality. The role of liver transplantation to treat unresectable metastases from NET is…
2020 American Transplant Congress
The Addition of Splenectomy to Simultaneous Liver Kidney Transplantation Improves Class II DSA Clearance in Sensitized Patients
V. Fleetwood, D. Aufhauser, C. Papageorge, K. Janek, L. Hidalgo, B. Welch, R. Redfield, J. Mezrich
Department of Transplantation, University of Wisconsin, Madison, WI
*Purpose: The liver allograft clears class I donor specific antibody (DSA) more effectively than class II DSA. Persistent class II DSA in simultaneous liver kidney…
2020 American Transplant Congress
Development of DSA Class II is Associated with Immunosuppressive Monotherapy and Increased Risk for Graft Fibrosis, Chronic Rejection and Graft Loss
M. Sterneck¹, B. Sultani¹, A. Ozga², S. Weidemann³, J. Hermann⁴, E. Grabhorn⁵, U. Herden⁶, L. Fischer⁶
¹University Medical Center Hamburg Eppendorf, Hamburg, Germany, ²Insitute of Medical Biometry, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ³Pathology, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ⁴Pediatric Radiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ⁵Pediatric Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ⁶Transplant Surgery, University Medical Center Hamburg Eppendorf, Hamburg, Germany
*Purpose: Recent studies have suggested a negative impact of class 2 DSA on short term outcome of OLT recipients. The aim of this study was…
2020 American Transplant Congress
Liver Transplant Recipients with High DSA at Time of Transplant Do Not Have Increased Rejection or Mortality
A. Demirag¹, B. Rawashdeh¹, S. L. Lennon¹, S. Pelletier¹, J. Iezzoni², K. Khutsisvhili³, S. Shumilina¹, K. Chittum¹, J. Oberholzer¹, P. Lobo⁴
¹Department of Surgery, University of Virginia Medical Cener, Charlottesville, VA, ²Department of Pathology, University of Virginia Medical Cener, Charlottesville, VA, ³Histocompatibility Laboratory, University of Virginia Medical Cener, Charlottesville, VA, ⁴Department of Medicine, University of Virginia Medical Cener, Charlottesville, VA
*Purpose: Currently, there is controversy regarding transplanting livers in setting of high HLA-class ll DSA especially since prior studies demonstrated enhanced acute rejections in this…
2020 American Transplant Congress
De Novo NAFLD Post-Liver Transplant is Defined by Altered Lipid Metabolism and Mitochondrial Dysfunction
M. Bhat¹, E. Pasini¹, M. Angeli¹, J. Allard², A. Humar¹
¹Multi-Organ Transplant, UHN, Toronto, ON, Canada, ²Division of Gastroenterology and Hepatology, UHN, Toronto, ON, Canada
*Purpose: De Novo Non-alcoholic Fatty Liver Disease (NAFLD) affects up to 35% of liver transplant (LT) recipients transplanted for non-NAFLD indications. Non-alcoholic steatohepatitis (NASH), the…
2020 American Transplant Congress
Functional Changes in Metabolic and Malignancy Associated Bacterial Genes in the Post Transplant Intestinal Microbiome
M. Bhat¹, S. Sivaraj¹, E. Pasini¹, J. Copeland², J. Allard³, A. Humar¹
¹Multi-Organ Transplant, UHN, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³UHN, Toronto, ON, Canada
*Purpose: Long-term survival of liver transplant (LT) recipients is affected by metabolic and malignant complications. The aim of our study was to examine changes in…
2020 American Transplant Congress
Comparative Review of Adult Kidney Transplant Medicare Cost Report Reimbursement in U. S. Transplant Hospitals
E. Zavala¹, J. Rogers², S. Karp¹
¹Vanderbilt University Medical Center, Nashville, TN, ²Transplant Management Group, San Diego, CA
*Purpose: Medicare organ acquisition reimbursement (MOAR) from the Medicare Cost Report (MCR) includes but is not limited to costs associated with candidate evaluation, maintenance on…